Clinical trials · North Carolina
Hematologic Malignancy clinical trials in North Carolina
We’re tracking 23 recruiting hematologic malignancy studies with a site in North Carolina — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in North Carolina
- NCT03537482RecruitingEarly Phase 1
Testing a new drug for blood cancers in adults
This early trial studies how safe and tolerable APG-2575 is, and how the drug moves through the body, in adults with certain relapsed or hard-to-treat blood cancers. It may help researchers learn whether the treatment could work better for people who have limited options.
Durham, North CarolinaAges 18 years+ - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Charlotte, North CarolinaAges 1–21 - NCT03328078RecruitingPhase 1/Phase 2
Emavusertib for recurrent brain lymphoma after prior treatment
This Phase 1/2 trial tests emavusertib (a targeted medicine) in adults with primary central nervous system lymphoma that has come back or not responded to treatment. It’s designed to find safe dosing and see how well the treatment can control the lymphoma in the brain/spinal fluid.
Durham, North CarolinaAges 18 years+ - NCT04588922RecruitingPhase 1/Phase 2
Study drug SLS009 for high-risk leukemia in adults and teens
This early-phase study tests SLS009 (also called GFH009), a targeted medicine, to treat certain blood cancers—especially high-risk or difficult-to-treat AML. It’s designed to see how the drug works, how safe it is, and what dose may be best for you.
Chapel Hill, North CarolinaAges 12 years+ - NCT02074839RecruitingPhase 1
Oral AG-120 for advanced blood cancers with an IDH1 mutation
This Phase 1 study tests an oral medicine called AG-120 in adults with advanced blood cancers that have a specific IDH1 mutation. It also looks at safety and how the treatment works, with frequent blood, urine, and bone marrow samples.
Durham, North CarolinaAges 18 years+ - NCT06823167RecruitingPhase 1
Study of IM-1021 for advanced cancers
This trial tests a new drug (IM-1021) for people with advanced cancers like lymphoma or solid tumors who have run out of standard options. The drug targets a protein called ROR1, which is found on some cancer cells, and may help shrink tumors or slow their growth.
Charlotte, North CarolinaAges 18 years+ - NCT06870760Recruiting
Early blood cancer detection in Charlotte firefighters
This study looks at firefighters to find early signs of blood cancers before they become serious. It aims to learn how to catch these cancers earlier, so they can be treated sooner.
Charlotte, North CarolinaAges 40–49 - NCT05768269Recruiting
Follow-up study for people previously treated with cellular therapy
This trial follows up with people who already received a Century Therapeutics cellular therapy treatment. It mainly checks how you’re doing over time and whether the treatment has lasting effects.
Charlotte, North CarolinaAges 18 years+ - NCT06532773RecruitingDurham, North CarolinaAges 18 years+
- NCT06533579RecruitingPhase 1/Phase 2
Gene therapy for CD19-positive blood cancers
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Chapel Hill, North CarolinaAges 13–90 - NCT07444268RecruitingPhase 1
Study of how DSP-5336 is processed in the body in advanced blood cancer patients
This trial looks at how your body absorbs, breaks down, and gets rid of the study drug DSP-5336 after a single dose. It is for people with advanced blood cancers that have come back or not responded to other treatments.
Chapel Hill, North CarolinaAges 18 years+ - NCT06665100RecruitingPhase 2
Study of PUL-042 for RSV and Related Viruses in Immune-Compromised Patients
This trial tests an inhaled medicine (PUL-042) for people with blood cancers or who have had a stem cell transplant and now have a respiratory virus (parainfluenza, RSV, or human metapneumovirus). The goal is to see if the drug can help clear the virus and improve symptoms.
Chapel Hill, North CarolinaAges 18 years+ - NCT03486873RecruitingPhase 3
Study extension for people on pembrolizumab, testing long-term safety
This trial follows people with advanced tumors who are already on pembrolizumab (or similar treatment) to check long-term safety and effectiveness. It may help your care team by monitoring benefits and side effects over a longer period.
Cary, North CarolinaAges 18 years+ - NCT06001788RecruitingPhase 1
Ziftomenib for relapsed or refractory acute myeloid leukemia
This trial tests a new drug combination called ziftomenib for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. Researchers will check how safe it is and what side effects happen.
Charlotte, North CarolinaAges 18 years+ - NCT06296368Recruiting
A tool to help older adults make cancer care decisions
This trial tests if a special tool can help adults aged 60 and older who are newly visiting a blood cancer or bone marrow transplant clinic understand their options and make decisions that fit their needs.
Chapel Hill, North CarolinaAges 60 years+ - NCT06731504RecruitingEarly Phase 1
Abatacept to prevent graft-versus-host disease after omidubicel stem cell transplant
This trial tests whether adding abatacept to standard care can reduce graft-versus-host disease (a condition where donor cells attack your body) after a stem cell transplant using a special cord blood product called omidubicel. It is for adults with blood cancers who have a suitable cord blood unit available.
Durham, North CarolinaAges 18 years+ - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Chapel Hill, North CarolinaAges 18–66 - NCT06989489Recruiting
Daily oral chemo adherence support program
This study is testing a program to help people stick with their daily oral chemo pill. It is for adults who have been taking a single oral cancer treatment for at least six months and want extra support.
Chapel Hill, North CarolinaAges 21 years+ - NCT07203534Recruiting
Virtual reality for pain and anxiety during bone marrow biopsy
This study tests if using a virtual reality headset during and after a bone marrow biopsy can help reduce pain and anxiety. If you are scheduled for this procedure, you may be able to participate.
Charlotte, North CarolinaAges 18 years+ - NCT01351545Recruiting
Cryopreserved cord blood access program for transplant patients
This trial studies an organized way to obtain and distribute unlicensed (not FDA-approved for general use) stored cord blood units that have been frozen and kept. It may help people who need a cord blood transplant but don’t fit the “licensed cord blood only” options.
Winston-Salem, North CarolinaAges Any age - NCT05332054Enrolling by invitation
Long-term follow-up after prior Caribou treatment
This study checks your health over time after you previously took a Caribou medicine (or got it through a special access program). It helps researchers learn what happens in the longer run after the treatment.
Charlotte, North CarolinaAges 18 years+ - NCT05041309Enrolling by invitation
Long-term follow-up after a Kite gene-cell infusion
This study checks on people long after they received a gene-modified cell infusion in a Kite-sponsored study. It helps researchers understand how treatments work over time and watch for any long-term effects.
Durham, North CarolinaAges Any age - NCT00920972RecruitingPhase 1/Phase 2
Bone marrow transplant prep for children with non-cancer blood disorders
This early-stage study tests a specific chemotherapy “conditioning” regimen to prepare the body for a bone marrow transplant in children with certain non-cancer blood or immune conditions. It may help the transplant work better, but it also carries risks from the chemotherapy and transplant process.
Charlotte, North CarolinaAges Up to 20 years
Hematologic Malignancy trials by city in North Carolina
Where these studies are running in North Carolina
Institutions with a site for the recruiting hematologic malignancy studies listed above.
- Levine Cancer Institute · 7 studies
- University of North Carolina at Chapel Hill · 7 studies
- Duke Cancer Center · 3 studies
- Duke University Medical Center · 2 studies
- Levine Children's Hospital · 2 studies
- UNC Lineberger Comprehensive Cancer Center · 2 studies
- 2400 Pratt Street
- Carolinas Medical Center/Levine Cancer Institute
What taking part in a hematologic malignancy study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Hematologic Malignancy trials in other states
Common questions
- Are there hematologic malignancy clinical trials in North Carolina?
- Yes. We're currently tracking 23 recruiting hematologic malignancy studies with a site in North Carolina, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a hematologic malignancy study in North Carolina?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in North Carolina to take part?
- Not necessarily. These studies have a site in North Carolina, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a hematologic malignancy trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New hematologic malignancy studies open in North Carolina regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.